If you or someone you care about is dealing with opioid dependence, understanding opioid treatment programs is the first practical step toward safer, more stable recovery. This article explains the main levels of care, compares medication options such as methadone, buprenorphine including Suboxone and Sublocade, and extended release naltrexone like Vivitrol, and outlines the behavioral therapies and recovery supports that make treatment work. You will also get a straightforward guide to choosing the right program, what to expect at intake, and how local clinics such as Resolutions Medical Services handle assessment, medication management, and aftercare.
How opioid treatment programs are organized and levels of care
Concrete fact: Opioid treatment programs are built around intensity of services, not a one-size-fits-all model — the right setting matches current risk, medical needs, and the patient life context.
How the levels translate to services
Think of levels as a ladder clinicians use to match services to danger and complexity. At lower intensity you get medication management plus weekly counseling and case work. As intensity rises you add structured therapy blocks, daily nursing and psychiatric oversight, supervised dosing, or 24-hour residential care for safety and stabilization.
- Outpatient: Medication-assisted treatment with regular visits and counseling — best when housing is stable and withdrawal risk is low.
- Intensive outpatient / Partial hospitalization: Several hours per day of therapy, plus medical oversight — used when employment or family responsibilities stay in place but substance use is frequent or there are co-occurring psychiatric problems.
- Residential treatment: Live-in care with therapy, medical monitoring, and structured days — appropriate for people with unstable housing, unsafe environments, or repeated treatment failures.
- Medically managed inpatient (detox): Short-term, clinician-supervised withdrawal management for high medical or psychiatric risk; must be followed by ongoing treatment to reduce relapse risk.
Key trade-off: Higher intensity reduces immediate risk but raises cost, time away from work or family, and logistic barriers. Lower intensity preserves daily life but requires stronger supports — stable housing, transportation, and active case management — to be effective.
Program mix matters: Most effective programs blend medication, counseling, and case management. Don’t assume an outpatient clinic only does prescriptions; ask whether they coordinate behavioral therapy, housing referrals, and naloxone training.
Concrete Example: A person leaving jail with active opioid use and no housing will usually need residential placement plus an immediate plan for medication-maintained care. By contrast, someone employed with steady housing and mild dependence often does well with office-based buprenorphine, weekly counseling, and telephone check-ins.
Common misunderstanding: People think detox is treatment. It is not sufficient on its own. Clinical experience and evidence show detox without a follow-up plan or medication-assisted therapy results in high relapse and overdose risk.
Actionable step: When you call a program, ask for the facility’s ASAM alignment, whether medications like methadone or buprenorphine are offered, and what step-down options exist. For system-level guidance see ASAM and for practical help finding local services, use SAMHSA Find Treatment. Resolutions Medical Services describes local services and intake steps on their services page.
Next consideration: be realistic about logistics. If transportation, childcare, or work shifts limit attendance, prioritize programs with flexible scheduling, telehealth follow-ups, and clear step-down plans so treatment intensity can change as stability improves.
Medication options explained: methadone, buprenorphine, and naltrexone
Main point: Choose the medication based on what you need to stabilize day-to-day life — safety, retention in care, and what your schedule allows matter more than brand names.
Methadone: clinic-based opioid maintenance
How it is delivered: Methadone is dispensed through licensed Opioid Treatment Programs (methadone clinics) with supervised dosing initially and a structured take-home schedule over time. Why it helps: It reliably reduces cravings and illicit opioid use and often keeps people in treatment longer when compared to other options. Trade-offs: daily clinic visits are a logistical barrier for many, and supervised dosing is required early in treatment; programs also monitor for medication interactions and cardiac risks clinically.
Buprenorphine: office-based and flexible
How it is delivered: Buprenorphine is available as sublingual films or tablets (Suboxone includes naloxone) and as monthly injectable formulations (Sublocade). It can be prescribed in office-based settings with fewer daily attendance requirements. Why clinicians choose it: Lower respiratory depression risk than full agonists makes it safer in many outpatient contexts, and take-home dosing supports work and parenting commitments. Limitations: induction requires careful timing to avoid precipitated withdrawal, especially with fentanyl exposure; diversion is a concern so programs use monitoring and formulation choices to reduce misuse.
Naltrexone: opioid antagonist with strict prerequisites
How it is delivered: Extended-release injectable naltrexone (Vivitrol) is given monthly but only after a patient is opioid-free. When it fits: Good for patients who prefer a non-opioid option or who cannot tolerate agonist therapy, and for those involved in certain legal or employment programs that require no opioid agonists. Practical constraint: the need to complete detox before starting reduces eligibility and is the main reason retention rates are lower versus agonist treatments.
- Retention vs access: Methadone often gives the best retention but imposes higher access burdens; buprenorphine balances retention and convenience; naltrexone gives no opioid protection if someone relapses.
- Pregnancy note: Methadone and buprenorphine are the accepted standards in pregnancy; naltrexone lacks robust evidence in this population.
- Overdose protection: Agonists (methadone, buprenorphine) reduce overdose risk while a patient remains on medication; naltrexone blocks opioids but offers no protection if doses are missed.
Concrete Example: A parent working two jobs with reliable housing usually benefits from office-based buprenorphine or monthly Sublocade to avoid daily clinic trips. By contrast, someone with unstable housing and frequent daily use may get faster stabilization and supervision at a methadone clinic where attendance and medical observation are structured.
Clinical judgment: In practice I start by asking what will keep the person connected to care. For most outpatients, buprenorphine is the pragmatic first-line because it lowers immediate overdose risk and fits ordinary life. Methadone is the better choice when prior buprenorphine attempts failed or when intense daily supervision is needed. Naltrexone is niche — useful but only for patients who can complete detox and commit to follow-up.
Actionable step: When you call a program ask whether they offer all three options, how they handle induction (including microinduction for buprenorphine if relevant), and whether they coordinate behavioral therapy. See Medication-Assisted Treatment and SAMHSA MAT resources for practical checklists.
Next consideration: match the medication to what will keep you in treatment — accessibility and safety beat theoretical superiority every time.
Behavioral and psychosocial therapies used alongside medications
Straight talk: medications reduce overdose risk and cravings, but behavioral care fixes the everyday problems that make relapse likely. Effective opioid treatment programs combine both deliberately — not as an afterthought, but as coordinated parts of a single plan.
What therapies do, and where they matter most
Core function: therapies teach skills, change routines, and address underlying issues like untreated depression, trauma, or unstable housing that medication alone cannot solve. Cognitive behavioral therapy builds relapse-prevention skills; motivational interviewing helps at the moment someone is ambivalent about staying in care; family therapy repairs relationships that support recovery.
Practical limitation: not every therapy fits every patient. CBT requires cognitive engagement and regular practice; someone actively withdrawing or with severe uncontrolled psychiatric symptoms may need stabilization before traditional therapy is effective. That is why programs must match modality to the patient, not force a one-size approach.
- Contingency management: tangible rewards for attendance or negative drug tests — one of the strongest ways to boost short-term retention but underused because it needs funding and clear policies.
- Peer recovery support: former patients trained as recovery coaches improve engagement and navigation of services, though credentialing and oversight vary.
- Integrated case management: addresses social determinants — housing, ID, benefits — which often predict whether someone stays in treatment more than the specific therapy model.
- Group therapy and community reinforcement: provide routine and peer norms; groups are efficient but need skilled facilitation to avoid triggering effects.
Judgment that matters: many clinics offer counseling only because it is billable; that is not sufficient for opioid use disorder. If a program pushes counseling as an alternative to medication, that is a red flag. Evidence and real-world outcomes show medication plus targeted psychosocial supports produce the best results for overdose prevention and sustained functioning.
Measurement-based care: good programs track symptoms, cravings, and functioning with simple tools (for example PHQ-9 for mood, standardized craving scales). Those data drive decisions — increasing session frequency, adding trauma-focused therapy, or referring to psychiatry — instead of relying on subjective impressions alone.
Concrete Example: A client started on buprenorphine struggles with follow-up because they lack stable housing. The clinic pairs weekly motivational interviewing to support engagement, contingency management for attending appointments, and a case manager who secures a temporary housing voucher. Within eight weeks the client keeps appointments, reduces illicit use, and transitions to monthly medication refills with continued therapy.
Trade-off to weigh: intensive psychosocial programming improves long-term gains but raises barriers — time, cost, and scheduling. Telehealth and evening group options reduce those barriers, but they require reliable technology and strong privacy protections. Ask whether a program offers a mix of in-person and virtual sessions and how it measures attendance and outcomes.
Ask your program whether they provide at least one evidence-based therapy (CBT, contingency management, or family therapy), a peer recovery specialist, and active case management — those three together move the needle.
Actionable check: When you call an opioid treatment program, request examples of how therapy is coordinated with medication visits, whether contingency management is used, and whether the clinic uses outcome measures. See Resolutions Medical Services’ service descriptions at services and their Medication-Assisted Treatment page for local practice patterns.
How to choose the right program for you or a loved one
Bottom line: pick the program the person will actually attend and stay with. Retention in care matters more for survival and functioning than theoretical differences between therapies.
A practical selection framework
Start by matching three realities: current medical risk, daily logistics, and motivation to engage. Medical risk covers escalation, pregnancy, and comorbid mental health disorders. Logistics covers work, transport, childcare, and legal obligations. Motivation covers readiness for medication, willingness to join groups, or ability to do outpatient work. Any program you consider should be able to meet at least two of those three immediately.
- Assess immediate safety: is there active daily use, recent overdose, or suicidal ideation? If yes, prioritize higher-intensity programs or medically managed care.
- Check for coordinated medical care: does the program integrate or refer for psychiatry, pregnancy care, and primary care?
- Confirm medication options: does the clinic offer methadone, buprenorphine (including office-based and injection options), and naltrexone, and how fast can they start you?
- Logistics and flexibility: hours, telehealth follow-ups, take-home policies, and weekend access — these determine whether attendance is realistic.
- Insurance and cost transparency: ask expected out-of-pocket per visit, whether Medicaid/insurance panels are accepted, and whether sliding scale or payment plans exist.
Trade-off to weigh: higher-intensity programs reduce immediate harm but increase time, cost, and disruption. Lower-intensity models preserve daily routines but rely on stable housing, reliable transport, and strong outpatient supports. Choose the least-disruptive option that still controls acute risk.
Questions to ask on the first call: How long between intake and first medication dose? Do you use microinduction for buprenorphine? How do you handle positive urine tests — punitive discharge or adjusted plan? Can you coordinate care with my obstetrician or probation officer if needed? These show whether a program is pragmatic or punitive.
Concrete Example: A pregnant person with opioid use disorder and prenatal care needs a program that coordinates with obstetrics, offers buprenorphine or methadone quickly, and provides case management for housing. A program that requires weeks of abstinence before medication is not appropriate for pregnancy because delays raise overdose risk and harm to the fetus.
Judgment call that matters: programs that foreground abstinence or counseling while delaying evidence-based medications are risky choices. In my experience, those clinics produce early dropout and higher relapse — not better outcomes.
If a program cannot start medication within a few days for someone at high risk, keep shopping. Immediate connection is prevention.
Actionable step: When you call, ask those practical questions and then compare two programs on wait time and flexibility. For local options and intake steps see Resolutions Medical Services services page or contact them via contact.
What to expect when you contact Resolutions Medical Services
Straightforward triage first: On first contact Resolutions focuses on immediate safety and access — clinicians will ask about last opioid use, recent overdoses, pregnancy status, and urgent withdrawal symptoms. Being direct about current use and medical history speeds appropriate placement and reduces the chance of a harmful delay.
First 24 to 72 hours – typical flow
- Rapid intake: A phone or secure online intake collects basic demographics, insurance details, and current risk. Expect a short screening to determine whether same-day medication start is possible.
- Insurance and paperwork: Staff will verify benefits and explain expected out-of-pocket costs. Resolutions can often help with authorizations or arrange a short bridge plan if approvals delay medication.
- Clinical assessment: A clinician reviews medical and psychiatric history, current medications, and performs a brief exam. Labs or a urine drug screen may be ordered depending on clinical need and the planned medication.
- Medication planning and induction: If medication-assisted treatment is appropriate, staff will explain options – methadone, buprenorphine (including office induction or microinduction), or naltrexone – and schedule induction or first dose timing.
- Care plan and supports: You will get a written, individualized plan covering medication follow-up, counseling frequency, case management referrals, and naloxone training or distribution.
Trade-off to know: Faster access and same-day starts reduce overdose risk but may mean initial counseling slots are limited. If rapid induction is necessary, expect tighter medical monitoring early and a plan to ramp up psychosocial supports once medication is stable.
Practical policy note: Resolutions uses monitoring and urine tests to guide care, not to punish. Clinics that discharge people for a single positive screen do more harm than good – real-world retention depends on flexibility and problem-solving, not rigid rules.
Concrete Example: A client actively using fentanyl called in the morning; staff arranged an observed buprenorphine microinduction the same afternoon, provided a monitored dose, and booked daily brief check-ins for the first week while arranging counseling and a housing referral. Within two weeks the client moved to twice-weekly medication visits and regular therapy sessions.
Quick step: Have your ID, insurance card, list of current medications, and a short timeline of last substance use ready. If privacy or legal concerns exist, mention them up front so clinicians can explain 42 CFR Part 2 protections and how records are shared. For more on intake and services see Resolutions services and Medication-Assisted Treatment.
If you need fast access, prioritize clinics that can offer same-day assessment or a bridge dose and that pair rapid starts with a clear plan for follow-up counseling and case management.
Next consideration: If wait times or rigid policies are a barrier, keep looking – timely, pragmatic access is a clinical intervention in itself and prevents avoidable risk.
Practical considerations: insurance, cost, telehealth, and safety
Key point: Insurance and clinic rules determine how fast you start treatment more often than clinical theory does. Commercial plans, Medicaid, and Medicare cover medication-assisted treatment differently, and prior authorizations or specialty pharmacy requirements can delay injectable products like Sublocade or Vivitrol.
Insurance and out-of-pocket cost realities
Practical reality: Expect three common hurdles – network status, prior authorization, and varying coverage for methadone treatment at opioid treatment programs. Ask whether the clinic is in-network, whether they will submit authorizations for you, and which pharmacies they use for injectables or extended-release medications.
Trade-off to consider: A lower copay plan is not always cheaper if it forces you to wait weeks for authorization. In practice, same-day or bridge medication starts with a modest out-of-pocket cost often prevent costly relapses and emergency care down the line.
Telehealth – what works and what does not
What you can expect: Most clinics provide telehealth for counseling and routine medication follow-ups. Office-based buprenorphine programs commonly use telemedicine for induction and early monitoring when clinically appropriate. Methadone still requires clinic dosing at licensed programs, so telehealth does not remove those attendance needs.
Limitation: Telehealth removes travel barriers but depends on stable phone or internet access and private space. If you lack reliable connectivity, insist the program offer phone-based check-ins, in-person backup visits, and clear instructions for emergencies.
Safety: overdose prevention and practical safeguards
Immediate actions clinics should provide: Naloxone distribution and training, a written safety plan for cravings or withdrawal, and clear instructions about drug interactions and other prescriptions. These are not optional extras – they are basic harm reduction built into good opioid treatment programs.
- Naloxone ready: Carry and know how to use naloxone; programs often provide kits and teach family members.
- Bridge planning: If prior authorization delays an injectable, a clinic should offer a short-term oral medication or observed dosing to protect you.
- Monitoring without punishment: Good programs use urine testing to tailor care, not to eject patients for setbacks.
Concrete Example: A single parent on Medicaid needed buprenorphine but had irregular internet and evening shifts. Resolutions arranged an afternoon in-person induction, issued a short bridge supply while authorizations processed for longer refills, scheduled telephone check-ins, and provided naloxone kits for the household. That mix of in-person and remote work kept the parent engaged and avoided an emergency room visit.
Judgment that matters: When choosing between lower cost and faster access, prioritize timely starts and pragmatic monitoring. Delays to medication or rigid attendance rules are common failure points I see clinically – they cost lives more than small out-of-pocket expenses do.
Actionable checklist: Before you enroll, verify in-network status, ask how the clinic handles prior authorization for injectables, confirm telehealth and phone options, and ensure naloxone is provided. For local logistics and intake steps see Resolutions Medical Services or contact them at contact.
Next consideration: confirm a program can start a protective medication quickly and provide naloxone before you commit to low-cost options that impose long waits.
Measuring progress and planning for long term recovery
Straight fact: Progress in opioid treatment programs should be judged by safer, more stable life markers and sustained engagement, not by a single clean urine or a short period of abstinence.
What to track — practical, measurable signals
- Engagement and adherence: appointment attendance, medication pick-ups or refill timing, and whether follow-up contacts are kept.
- Functioning measures: steady housing, employment or education participation, parenting stability, and reduced legal problems — these matter more than perfect test results.
- Patient-reported outcomes: standardized screens for cravings, mood (PHQ-9), sleep, and medication side effects to guide adjustments.
- Clinical safety signals: overdose events, emergency visits, naloxone use, and new medical issues that require faster escalation.
- Biological data with caveats: urine drug screens and medication levels help, but panels vary (fentanyl may be missed on some tests) and results must be interpreted in context.
Practical insight: Use a small dashboard of 4–6 indicators and review them routinely. Too many metrics creates noise; too few misses problems. A weekly check on attendance and cravings plus monthly functioning review is a workable starting cadence in most outpatient settings.
Adjusting the plan and responding to setbacks
Key trade-off: Strict abstinence policies can improve short-term test scores but drive people out of care. Programs that emphasize continuity and problem-solving retain people and reduce overdose risk — that is the pragmatic, evidence-aligned choice.
- Minor setback (isolated use or missed visit): increase contact frequency, add contingency supports, check for triggers, do not discharge.
- Repeated positive tests or worsening mood: step up psychosocial services, reassess medication fit (e.g., induction approach or formulation), and consider concurrent psychiatric treatment.
- Acute safety event (overdose, suicidal ideation): move immediately to higher intensity care or hospitalization and update the long-term plan before stepping down.
Judgment that matters: Clinically, tapering off medication is a valid goal for some but should be deliberate and slow when considered. Early discontinuation is the most common pathway to overdose after treatment; staying on medication while building supports is usually safer than rushing to stop.
Concrete Example: A client on buprenorphine had irregular attendance and three positive urine tests in two months. The clinic increased telehealth check-ins, added contingency management for on-time visits, involved a peer recovery coach, and coordinated with housing services. Six weeks later the client stabilized, missed fewer appointments, and reported fewer cravings — the measurable improvement guided the decision to keep medication in place rather than start a taper.
Progress is multi-dimensional: fewer overdoses, steady engagement, and improved daily functioning are the real signals that long-term recovery is working.
90-day checklist: confirm medication adherence, document housing/employment status, administer PHQ-9 and a craving scale, supply naloxone and update emergency plan, and schedule a formal medication review. For clinic-level tools and protocols see SAMHSA MAT and local service options.
Frequently Asked Questions
Direct point: Quick answers are useful, but the right option depends on individual risk, daily logistics, and what will keep someone connected to care. Below are clear, practical replies to the questions people actually ask when they call a clinic.
Short answers to the most common concerns
Are medications like Suboxone or methadone merely swapping one addiction for another? No. These medications are evidence based treatments that stabilize brain function, reduce cravings, and cut overdose risk. When combined with counseling and supports, they improve retention and daily functioning. That is the clinical goal, not replacement for recovery work.
How long must someone stay in treatment? Duration is individualized. Many clinicians recommend at least 12 months of medication supported care for durable benefit, but some people remain on medication longer. The main rule is to make any taper a planned, gradual clinical decision rather than a rushed endpoint.
Can medication assisted treatment start if a person is still using opioids? Yes in many cases. Office based buprenorphine can be initiated using microinduction or carefully timed induction to reduce precipitated withdrawal, and methadone induction happens at licensed clinics. Naltrexone requires an opioid free window first, which is why it is not appropriate for everyone. Example use case: A person on probation who must avoid opioid agonists completed a short inpatient detox, then began monthly injectable naltrexone with coordinated counseling and legal case coordination. That sequence met the legal requirement while providing medical supervision and psychosocial supports.
Will my employer or family be notified if I start treatment? Treatment records are protected but not absolute. 42 CFR Part 2 provides strong confidentiality for substance use disorder programs, but there are exceptions for medical emergencies, certain court orders, and mandatory reporting like child safety concerns. Ask the clinic to explain how they handle disclosures and what consents they will request.
What if cost or insurance is a barrier? Many clinics take Medicaid and commercial plans and will help with authorizations or short term bridge medication when approvals delay care. If finances are a major barrier, request a benefits check during the first call and ask about sliding scale options or community funded resources.
Privacy snapshot: 42 CFR Part 2 guards substance use treatment records in most routine situations. Tell intake staff about legal or custody concerns so they can explain limits of confidentiality and offer alternatives.
One practical judgment: Clinics that delay medication for ideological reasons or require long abstinence before offering proven treatments produce avoidable harm. Prioritize programs that will stabilize you quickly and then layer in counseling, case management, and relapse prevention.
- Action 1: Collect ID, insurance card, list of current medications, and a short timeline of last use before you call a program.
- Action 2: Ask on first contact whether the clinic can offer same day or next day medication starts and what bridge options exist while authorizations process.
- Action 3: Request naloxone and training at intake and confirm how the clinic handles urine testing or missed visits.
- Action 4: If you have pregnancy, probation, or custody concerns, mention them up front so the intake team can coordinate with relevant providers.
Next step: If you are local, see Resolutions Medical Services intake and services pages for logistics and contact options.